Targeting IL-6 in the treatment of inflammatory and autoimmune diseases

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1457-1466

  Ding, Changhai ^a,b   Cicuttini, Flavia ^a   Li, Jun ^c   Jones, Graeme ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune diseases; IL 6; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ATLIZUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE;

ABSCESS; ACUTE PYELONEPHRITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTHRITIS; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BLADDER CANCER; BREAST CANCER; BREAST PAPILLOMA; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ERYTHROPHAGOCYTOSIS; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HUMAN; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; INFECTION; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LARGE INTESTINE CANCER; LIMB ABSCESS; LIVER DISEASE; LIVER TOXICITY; LUNG INFECTION; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NONHUMAN; OSTEOMYELITIS; PNEUMONIA; POLYARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6;

EID: 70349319715     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903203789     Document Type: Review

References (42)

1. Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials 2006;1(3):193-200 • A comprehensive review to describe the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in the treatment of inflammatory and autoimmune diseases.
2. Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S11-15
3. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4-10
4. Imagawa T, Mori M, Takei S, et al. Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis. Arthritis Rheum 2006;54(9):S168-S168
5. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5(12):1731-1740 (Pubitemid 41116745)
6. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8(Suppl 2):S2
7. Ding C, Jones G. Technology evaluation: MRA, Chugai. Curr Opin Mol Ther 2003;5(1):64-69
8. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003;30(7):1426-1435 (Pubitemid 36835435)
9. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-2829 • This clinical trial suggested that tocilizumab, both as monotherapy and as combined therapy, was efficacious in decreasing disease activity of RA. A dose response was observed and tocilizumab at a dose of 8 mg/kg was most effective. (Pubitemid 44497760)
10. Jones G, Gu JR, Lowenstein M, et al. The AMBITION study: superiority of tociluzumab (TCZ) vs methotrexate (MTX) monotherapy in patients with rheumatoid arthritis (RA). Ann Rheum Dis 2009;68:online •• It is an international multicenter clinical trial suggesting that tocilizumab monotherapy was superior to methotrexate in the treatment of RA.
11. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46(12):3143-3150 • It is the first randomized controlled trial showing that inhibition of IL-6 significantly improved the signs and symptoms of RA. (Pubitemid 35453522)
12. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50(6):1761-1769 (Pubitemid 38725087)
13. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66(9):1162-1167 •• This randomized control clinical trial suggests that tocilizumab may have disease-modifying effects in the treatment of RA. (Pubitemid 47309731)
14. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19(1):12-19
15. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2008 [Epub ahead of print] • This study reported that targeting IL-6 for long term (≤ 5 years) was safe and efficacious for RA.
16. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-997 • A randomized controlled trial suggesting tocilizumab plus methotrexate therapy was superior to methotrexate therapy for RA.
17. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58(10):2968-2980 •• A multicenter trial with large sample size suggesting that tocilizumab in combination with traditional disease-modifying drug therapy was more efficacious than only disease-modifying drug therapy for RA.
18. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-1523 • A randomized controlled trial suggesting that in patients with RA responding inadequately or who are intolerant to TNF antagonists, changing to tocilizumab either as monotherapy or in combination is effective and safe.
19. Emery P, Keystone E, Tony HP, et al. Patients achieve significant improvement in rheumatoid arthritis (RA) outcomes with tociluzumab (TCZ) regardless of prior inadequate response (IR) to TNF antagonists. Arthritis Rheum 2008;58(9):S533-S533
20. Kremer JM, Fleischmann RM, Halland AM, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. Arthritis Rheum 2008;58(12):4031-4031
21. Gamero P, Mareau E, Thompson L, Woodworth T. The anti-IL6 receptor inhibitor tocilizumab (TCZ) combined with methotrexate (MTX) induces a rapid and sustained decrease of bone and cartilage degradation in patients with rheumatoid arthritis (RA). Arthritis Rheum 2008;58(9):S534-S534
22. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005;7(6):R1281-8
23. Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52(3):818-825 (Pubitemid 40365104)
24. Yokota S, Miyamae T, Kurosawa R, et al. Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra (R)). Arthritis Rheum 2005;52(9):S725-S725
25. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371(9617):998-1006 •• A Phase III study suggesting targeting IL-6 by tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis.
26. Yokota S, Imagawa T, Miyamae T, et al. Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials. Arthritis Rheum 2008;58(9):S631-2
27. Inaba Y, Ozawal R, Imagawa T, et al. Radiologic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following treatment with tocilizumab, anti-IL 6 receptor monoclonal antibody. Ann Rheum Dis 2007;66:550-551
28. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8):2627-2632 (Pubitemid 41510733)
29. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95(1):56-61 (Pubitemid 30017224)
30. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126(4):989-96; discussion 947 (Pubitemid 38451170)
31. Shirota Y, Yarboro C, Sims G, et al. The impact of in vivo anti IL-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52(9):S697-S697
32. Illei GG, Yarboro C, Shirota Y, et al. Tocilizumab (humanized anti IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Arthritis Rheum 2006;54(12):4043-4043
33. Smolen JS, Beaulieu AD, Dikranian A, et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S784-S784
34. Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 2006;65(12):1667-1669 (Pubitemid 44799688)
35. van Vollenhoven RF, Smolen J, Tony HPT, et al. Safety of tocilizumab in patients with rheumatoid arthritis: an interim analysis of long-term extension trials with a mean treatment duration of 1.5 years. Arthritis Rheum 2008;58(9):S784-5
36. Kremer JM, van Vollenhoven RF, Ridley DJ, et al. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow-up duration of 1.5 years. Arthritis Rheum 2008;58(9):S783-4
37. Kremer JM, Joh AK, Malamet R, Keystone EC. Hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S783-S783
38. Genovese MC, Smolen JS, Emery P, et al. Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S531-2
39. Genovese MC, Smolen JS, Emery P, et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: analysis of five phase 3 clinical trials. Arthritis Rheum 2008;58(9):S785-6
40. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002;8(1):75-79 (Pubitemid 34101732)
41. Ramos-Remus C, Genovese MC, Harre RA, et al. Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: analysis of four phase 3 clinical trials. Arthritis Rheum 2008;58(9):S534-S534
42. Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 2008;26(9):957-959